Lauren Buchanan, MA, Managing Editor

The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Improvements persisted through the 12-week post-treatment follow-up, indicating sustained efficacy even after discontinuation of dupilumab.

Four leaders in HS treatment and care put a spotlight on the latest clinical trial data and treatment techniques.

Terry Arnold, PA-C, shared his journey and advice for PAs and NPs looking to transition out of a clinical practice.

Significant improvements were observed in EASI scores across all anatomical regions, regardless of patient age or specific body region.

Dermatology Times will bring clinical insights from leading experts in numerous dermatology specialties.

Whether you are attending in-person or looking to Dermatology Times coverage, let us know which topics interest you most.

ICYMI: 5 news headlines that impact the treatment of scars, wounds, melanoma, and other skin conditions impacting veterans and active military personnel.

While MMS is recognized as the gold standard for skin cancer treatment, numerous challenges still hinder widespread adoption and practice.

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

A recent study spotlights an opportunity for interdisciplinary collaboration between dermatologists and orthodontists.

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

The analysis revealed a higher rate of discontinuations due to immune-mediated adverse experiences.

A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.

Leading dermatologists explore key benchmarks, emerging trends, personalized medicine approaches, and more in atopic dermatitis.

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

ASLAN Pharmaceuticals presented new data this morning, including a 90% EASI score reduction.

Brian Kim, MD, had an unexpected attendee at one of his AAD sessions and delves into what's new, what's now, and what's next in atopic dermatitis management.

Dozens of investigators shared findings to advance care in patients with melanoma during Mohs micrographic surgery.

The Harris brothers serve 2 predominantly elderly populations and appreciate the opportunity to provide solutions for the growing complexity of skin cancer issues as patients live longer.

A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.

Study findings suggest OCT's effectiveness in accurately diagnosing and mapping BCC, with a high predictive capability for Mohs surgery requirements.

A recent survey covered topics including skin-aging prevention, care-seeking behavior, trust in professionals, and more.

Chinese clinical researchers recently presented a unique case of JLIS manifesting as erythematous papules and infiltrative plaques on the nose and upper jaw, resembling rosacea.

The European approval was based on data from the Phase III BE HEARD I and BE HEARD II trials.

The FDA has released guidelines for clinicians and tips to identify the distinguishing features of counterfeit products.

Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.